Elan Corp. and Transition Therapeutics, Inc reported results from a Phase II study of ELND005 (Scyllo-inositol) in patients with mild to moderate Alzheimer’s disease. The placebo-controlled study included 351 patients who received ELND005 for up to 18 months (Study AD201). Study subjects with MMSE scores between 16 and 26 received ELND005 oral doses of 250 mg, 1000 mg or 2000 mg twice daily or matching placebo. The study’s cognitive and functional co–primary endpoints did not achieve statist...